Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2022 | Story Lacea Loader | Photo Sonia Small (Kaleidoscope Studios)
Dr Engela van Staden
Dr Engela van Staden, Vice Rector: Academic

The University of the Free State (UFS) has finalised the first part of the Council on Higher Education (CHE) Institutional Audit (IA), submitting its Institutional Self-Evaluation Report (SER) and Portfolio of Evidence (PoE) to the higher education quality assurance body. 

According to Dr Engela van Staden, Vice-Rector: Academic, the second part of the institutional audit will involve the participation of relevant stakeholders in a site visit to the institution. During the visit, scheduled between 9 and 13 May 2022, an external panel of experts will systematically assess the submitted SER and requisite documents by asking inquisitive questions to interviewees who will be participating in this process.  

“The focus will be on the quality of programme offerings with a view to improving student success in all spheres of the student walk – from registration to graduation. To this end, the university’s Integrated Quality Management Framework (IQMF) will be assessed in order to provide evidence that quality assurance is ingrained in the core functions of the UFS, i.e., student success; quality of teaching and research; and engaged scholarship.”

Dr Van Staden says by re-introducing the SER, the university will embark on a stakeholder engagement plan, engaging with staff in faculties, service units, directorates, centres, departments, or schools, to keep them informed and prepared for a productive contribution to the Institutional Audit process. 

- The CHE is an independent statutory body established in terms of the provisions of the Higher Education Act No. 101 of 1997, as amended. It advises the Minister responsible for Higher Education and Training and is the national authority for quality assurance and promotion in higher education.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept